Integer Holdings Beats Q4 with 5% Sales Growth, $1.76 EPS and $100M Buyback
Integer Holdings reported Q4 sales of $472.1 million, up 5% year-on-year and 2% above estimates, with adjusted EPS of $1.76, 3.6% above consensus. It guided FY26 adjusted EPS to a $6.54 midpoint (3.8% above forecasts), cited 3–4% temporary product headwinds and highlighted $100 million in share repurchases.
1. Q4 Results
Integer Holdings delivered Q4 revenue of $472.1 million, up 5% year-on-year and 2% above expectations, with adjusted EPS of $1.76 (3.6% beat) and adjusted EBITDA of $106 million (22.5% margin). Organic revenue rose 2%, driven by strength in the Cardio & Vascular segment from recent acquisitions and neurovascular demand.
2. Guidance and Outlook
For fiscal 2026, management guided to a $6.54 adjusted EPS midpoint (3.8% above forecasts) and $402.5 million in EBITDA, noting 3–4% temporary headwinds from three low-adoption products. Operating margins are expected to improve in the second half as sales recover and free cash flow remains a priority.
3. Management Commentary
Management attributed $30 million of operational improvements to manufacturing efficiencies and expense discipline, while emphasizing a product development pipeline that has grown 300% since 2017, focused on high-growth areas like electrophysiology and neuromodulation.
4. Capital Allocation
The company repurchased $50 million of shares during the quarter and initiated a $50 million accelerated share repurchase, underscoring its disciplined capital allocation strategy aimed at boosting long-term shareholder value.